Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2 Active not recruiting 134 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupOpen-labelTreatment

The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma

Evaluation	Drug	Modality	Dose	Route
Subject	LTT462	Unknown	—	Oral
Subject	Naporafenib	Small molecule	—	Oral
Subject	Ribociclib	Small molecule	—	Oral
Subject	Trametinib	Small molecule	—	Oral